Singapore markets closed
Straits Times Index
3,307.90 -6.15 (-0.19%) Nikkei
38,946.93 -122.75 (-0.31%) Hang Seng
19,220.62 -415.60 (-2.12%) FTSE 100
8,416.45 -7.75 (-0.09%) Bitcoin USD
69,964.59 +80.10 (+0.11%) CMC Crypto 200
1,518.07 +29.52 (+1.98%)
Daiichi Sankyo Company, Limited (DSNKY)
Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
At close: 03:59PM EDT
| Previous close | 35.40 |
| Open | 35.17 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 34.99 - 35.25 |
| 52-week range | 23.72 - 37.57 |
| Volume | |
| Avg. volume | 199,448 |
| Market cap | 67.524B |
| Beta (5Y monthly) | 0.26 |
| PE ratio (TTM) | 52.40 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.24 (0.69%) |
| Ex-dividend date | 28 Sept 2023 |
| 1y target est | N/A |
- Business Wire
Daiichi Sankyo Highlights Progress in Creating New Standards of Care for Patients Across Multiple Cancers at ASCO
BASKING RIDGE, N.J., May 21, 2024--Daiichi Sankyo Highlights Progress in Creating New Standards of Care for Patients Across Multiple Cancers at ASCO
- Business Wire
ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial
TOKYO & BASKING RIDGE, N.J., April 29, 2024--ENHERTU Showed Statistically Significant & Clinically Meaningful Improvement in PFS in HR Positive, HER2 Low mBC Following ET in DESTINY-Breast06
- Business Wire
ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors
TOKYO & BASKING RIDGE, N.J., April 06, 2024--ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2+ Solid Tumors
© 2024 Yahoo. All rights reserved.